Chemotherapy combined with or without targeted therapy is the fundamental treatment for
metastatic colorectal cancer (mCRC). Due to the adverse effects of chemotherapeutic drugs …

Cancer immunotherapy offers substantive benefit to patients with various tumour types, in
some cases leading to complete tumour clearance. However, many patients do not respond …

Background Interferon-γ (IFN-γ) plays a key role in activation of cellular immunity and
subsequently, stimulation of antitumor immune-response. Based on its cytostatic, pro …

Immune checkpoint blockade is effective for some patients with cancer, but most are
refractory to current immunotherapies and new approaches are needed to overcome …

The immune system can eliminate tumors, but checkpoints enable immune escape. Here,
we identify immune evasion mechanisms using genome-scale in vivo CRISPR screens …

T cell exhaustion presents one of the major hurdles to cancer immunotherapy. Among
exhausted CD8+ tumor-infiltrating lymphocytes, the terminally exhausted subset contributes …

Chimeric antigen receptor (CAR) T cell therapy targeting CD19 has achieved tremendous
success treating B cell malignancies; however, some patients fail to respond due to poor …

The T cell receptor (TCR) complex is a naturally occurring antigen sensor that detects,
amplifies and coordinates cellular immune responses to epitopes derived from cell surface …

Chimeric antigen receptor (CAR) T cell therapy relies on the activity of a large pool of tumor-
targeting cytotoxic effectors. Whether CAR T cells act autonomously or require interactions …

Immune checkpoint blockade targeting PD-1/PD-L1 has promising therapeutic efficacy in a
variety of tumors, but resistance during treatment is a major issue. In this review, we describe …